Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
25 November, 2017 03:24 IST
Zydus Cadila gets USFDAs final nod for Phentermine HCl tablets
Source: IRIS | 30 Jun, 2017, 10.10AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Phentermine Hydrochloride Orally Disintegrating Tablets in strengths of 15 mg, 30 mg, and 37.5 mg.

The drug is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Shares of the company gained Rs 3.55, or 0.68%, to trade at Rs 525.45. The total volume of shares traded was 16,403 at the BSE (10.03 a.m., Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Indian Hume Pipe secures order worth Rs 1.19 bn - 24-Nov-2017 15:14
Arshiya signs definitive agreements with Ascendas - 24-Nov-2017 11:20
IMP Powers commissions 20 KW hydro-kinetic project - 24-Nov-2017 10:38
Reliance concludes sale of certain assets operated by Carrizo Oil & Gas - 24-Nov-2017 10:25
Zydus Cadila gets USFDA nod for Minocycline HCl ER tablets - 24-Nov-2017 10:22
Zydus Cadila gets tentative approval for Tadalafil tablets - 24-Nov-2017 10:19
Skipper to form JV with MetzerPlas Co-op Agricultural Organization - 24-Nov-2017 10:15
CG Power bags order worth Rs 1.11 bn from Indian Railways - 24-Nov-2017 10:09
Welspun Corp bags order for supply of 392K MTs pipes - 24-Nov-2017 10:04
Thomas Cook to sell 5.42% stake in Quess Corp via OFS - 23-Nov-2017 10:28
Tata Tele subscribers commence transitioning to Airtel network - 23-Nov-2017 10:13
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer